The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously.
Borderline epithelial ovarian tumours (BOT) were described 70 years ago as semimalignant tumours (Taylor, 1929) , although diagnostic criteria were not refined until the early 1970s (International Federation of Gynaecology and Obstetrics, 1971; Serov et al, 1973) . The diagnosis is made on histological criteria that there is epithelial proliferation, multilayering and atypical cytological features but an absence of destructive stromal invasion (Scully et al, 1979) . The majority of these tumours are of serous or mucinous subtype, the latter being of intestinal or Müllerian type.
BOT can also be classified according to the presence of extraovarian, peritoneal disease. While peritoneal disease (implants) may be seedlings (superficial metastases) in the pelvic peritoneum, many of them represent foci of peritoneal metaplasia. The epithelium in these latter foci may be benign (endosalpingiosis) but may show the same characteristics as that in the ovarian neoplasm (Gershenson et al, 1990; Bell et al, 1991; Kurman and Trimble, 1993; Michael et al, 1993) . Serous implants may also be subdivided into non-invasive (desmoplastic and epithelial) and invasive types (Michael and Roth, 1986; Bell et al, 1988) ; the latter can be treated as an invasive malignant tumour (Bell et al, 1988) . Furthermore serous borderline tumour with microinvasion (individual or clusters of cells) (Tavassoli et al, 1988; Bell and Scully, 1990) has also been described. Mucinous tumours of intestinal type can be associated with pseudomyxoma peritoneii and there is evidence that some of these tumours may be metastases from a primary adenoma or adenocarcinoma of the vermiform appendix (Hinson and Ambrose, 1998) .
The survival of patients with BOT is good. In a review of 953 patients that excluded those with invasive implants the survival of patients with stage I disease and stage III disease was 99% and 92% respectively at a median of 7 years follow-up (Kurman and Trimble, 1993) . However, other reports have shown that the disease can follow an indolently progressive course with a 30% relapse rate over 7 years after diagnosis (Gershenson et al, 1998) . Nevertheless, these survival statistics are significantly better than those for ovarian cancer.
The principal modality of treatment for BOT is surgery, whereas ovarian cancer is largely treated with surgery and chemotherapy. Thus the incorrect ascription of a diagnosis of ovarian cancer to a patient who has BOT will result in the patient receiving chemotherapy and incorrect information concerning long-term survival. In addition a correct diagnosis of BOT in a younger woman would allow the preservation of fertility. This study reports the results of expert histopathological review of cases that were finally managed as having BOT.
MATERIALS AND METHODS
The pathology of all cases of ovarian neoplasms referred to the Department of Medical Oncology (Christie Hospital National Health Trust) is reviewed by pathologists with a special interest in gynaecological oncology (Serov et al, 1973) . The patients who were managed as having BOT between 1988 and 1997 were included in this study. Prospective demographic information was gathered and the FIGO stage was determined through a summation of pathological, clinical and radiological findings (FIGO, 1971) .
RESULTS
Sixty-four patients with a diagnosis of BOT, following pathology review, were identified for the study. Their demographic details are shown in Examination of the original pathology report (issued before specialist pathology review) showed that in 27 cases (42.2%) the original diagnosis was of an invasive carcinoma of the ovary. In 17 cases these were described as well differentiated tumours and in two cases as moderately differentiated tumours. The differentiation status was not described in the remaining eight cases. Twentythree of the cases originally described as carcinomas were not associated with peritoneal involvement; the remaining four were associated with non-invasive implants. Of the cases originally described as carcinomas, 11 were FIGO stage I tumours (three stage Ia; one stage Ib; seven stage Ic), five were stage II tumours and ten stage III tumours (Table 1) .
Ten of the 64 patients (including five originally described as carcinoma) with borderline tumours received chemotherapy. One of the patients that received chemotherapy had stage II disease and the rest had stage III disease. Of the nine patients that could be assessed for response, there was one complete response and one partial response. Five patients had a second laparotomy after chemotherapy.
The median follow-up for these patients was 3.1 years (range 40 days to 12.1 years). There were seven disease-related deaths and one intercurrent death; 46 patients remain alive and disease-free; nine are alive with stable disease; one is alive with recurrent disease. Of the patients who received chemotherapy, four were disease-free at follow-up, three had stable disease, one was alive with recurrent disease, two had died of disease. In two cases there was histopathologically confirmed malignant transformation to invasive carcinoma (one death). The 5-year event-free survival (death, progression or recurrence) for stage I and II patients versus stage III was 87% and 53% respectively (P = 0.01). However, a comparison between the event-free survival for the group initially diagnosed with carcinomas and that of the group where the diagnosis was not changed, revealed no difference between the groups with a 70% 6-year event-free survival (P = 0.5) (Figure 1) .
DISCUSSION
This is a study of 64 patients with a diagnosis of borderline ovarian cancer managed at a specialist centre. The patients had been referred from other hospitals in the region and this accounts for the atypical distribution of FIGO stage in patients with BOT. Although only a minority of patients received chemotherapy, the prognosis for these tumours is good, with a 79% 5-year survival from diagnosis. However, patients with FIGO stage III disease had a worse prognosis. Interestingly, nearly 40% of the patients gave a family history of another epithelial cancer, a finding that has not been reported previously in studies of patients with BOT.
The most striking feature of this study was the finding that in 27 cases (42.2%) the original diagnosis was of invasive ovarian carcinoma prior to specialist gynaecological oncology pathology review. However, of the 27 cases where the diagnosis was revised, only four were FIGO stage Ia-Ib. The remaining cases were FIGO stage Ic-III (one unknown) and would have received chemotherapy had the diagnosis not been changed. There was no difference in event-free survival between the group that had a changed histopathological diagnosis and those with an unchanged diagnosis (P = 0.5). This high frequency of change in diagnosis may be due to the referral bias that led to a high proportion of advanced-stage patients in the series. OVCA (6/27) P = 0.5 Alive and relapse-free (%) Figure 1 Comparison of event-free survival of patients (BOT: patients originally diagnosed as having borderline ovarian tumours; OVCA: patients originally diagnosed as having invasive ovarian tumours). Note one case in the BOT group was missing necessary information and hence has been omitted here
Coupled with the long event-free survival that compares with other BOT series, the implication is that borderline tumour was the correct designation. As chemotherapy is associated with early and late morbidity and mortality, most patients with BOT will be spared these toxicities and clinicians will give patients the correct information concerning prognosis. These data support the need for expert histopathological evaluation of ovarian tumours.
